Davita Inc (NYSE:DVA) CEO Javier Rodriguez sold 22,532 shares of the stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $67.48, for a total value of $1,520,459.36. Following the completion of the transaction, the chief executive officer now owns 210,317 shares of the company’s stock, valued at $14,192,191.16. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Davita Inc (DVA) opened at $69.51 on Tuesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The company has a market capitalization of $12,814.77, a PE ratio of 19.35, a PEG ratio of 13.65 and a beta of 0.97. Davita Inc has a 12 month low of $52.51 and a 12 month high of $70.16.
Davita (NYSE:DVA) last issued its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). The firm had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. Davita had a net margin of 3.40% and a return on equity of 13.31%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 earnings per share. analysts anticipate that Davita Inc will post 3.42 earnings per share for the current year.
Davita announced that its Board of Directors has approved a stock buyback plan on Tuesday, October 10th that permits the company to repurchase $1.50 billion in shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
DVA has been the subject of several analyst reports. J P Morgan Chase & Co raised their target price on Davita from $4.90 to $84.00 and gave the stock a “strong-buy” rating in a research report on Thursday, December 7th. Robert W. Baird reaffirmed a “hold” rating and set a $63.00 target price on shares of Davita in a research report on Friday, November 10th. Citigroup raised Davita from a “neutral” rating to a “buy” rating and raised their target price for the stock from $67.71 to $82.00 in a research report on Monday. SunTrust Banks set a $70.00 target price on Davita and gave the stock a “hold” rating in a research report on Thursday, December 7th. Finally, Zacks Investment Research downgraded Davita from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, two have given a buy rating and two have given a strong buy rating to the company. Davita presently has an average rating of “Hold” and an average price target of $71.22.
Institutional investors and hedge funds have recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Davita in the 3rd quarter valued at about $154,000. Pzena Investment Management LLC grew its stake in shares of Davita by 2.1% in the 2nd quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after buying an additional 71 shares during the period. Eqis Capital Management Inc. boosted its stake in Davita by 62.5% during the 3rd quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock valued at $444,000 after purchasing an additional 2,873 shares during the last quarter. Jensen Investment Management Inc. boosted its stake in Davita by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock valued at $631,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Accident Compensation Corp boosted its stake in Davita by 147.5% during the 2nd quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock valued at $978,000 after purchasing an additional 9,000 shares during the last quarter. Institutional investors own 85.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Davita Inc (DVA) CEO Javier Rodriguez Sells 22,532 Shares” was published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.truebluetribune.com/2017/12/12/davita-inc-dva-ceo-javier-rodriguez-sells-22532-shares.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.